The Guidant Ventak Prizm 2 DR — a Hidden Flaw, a Dead 21-Year-Old, a Guilty Plea

When Guidant Corporation issued its physician advisory on June 17, 2005 and the FDA classified it a Class I recall — the most serious category, reserved for defects with a reasonable probability of serious injury or death — the gap between the device’s promise and its performance had already been measured in a single funeral. The Ventak Prizm 2 DR (Model 1861) was an implantable cardioverter-defibrillator, a machine whose entire purpose is to deliver a life-saving shock at the instant a patient’s heart fibrillates. Guidant had known since February 2002 that a fraction of these units were prone to internal electrical arcing — a short-circuit across degraded insulation that could render the device inert exactly when it was called upon to fire. The company quietly re-engineered the device in November 2002 to fix the flaw, then told the FDA the change did not affect safety or effectiveness, and continued shipping the older, defect-prone inventory it had already built.

The concealed defect became a body on March 14, 2005, when Joshua Oukrop, a 21-year-old college student from Grand Rapids, Minnesota, with hypertrophic cardiomyopathy, collapsed and died on a mountain-biking trip in Utah. His implanted Prizm 2 DR had short-circuited and failed to shock him. His electrophysiologists, Dr. Robert Hauser and Dr. Barry Maron of the Minneapolis Heart Institute, asked Guidant what had happened; the company disclosed that it knew of the failure mode but had no plan to warn physicians. Hauser and Maron took the case to The New York Times, whose reporter Barry Meier published it on May 24, 2005. Public exposure, not the manufacturer’s conscience, forced the recall three days later.

The reckoning was not regulatory but criminal. After a four-year investigation, the U.S. Department of Justice charged Guidant — by then a subsidiary of Boston Scientific, which had acquired it for roughly $27 billion in April 2006 — with making a materially false statement to the FDA about the Prizm 2 DR and failing to report a “correction” to its Contak Renewal defibrillators. Guidant pleaded guilty, and on January 12, 2011 U.S. District Judge Donovan W. Frank in St. Paul ordered it to pay more than $296 million in fines and forfeiture and serve three years of supervised probation — at the time the largest criminal penalty ever imposed for violating the Food, Drug, and Cosmetic Act. The episode became the foundational case for the principle that withholding a known device defect from regulators is not a paperwork lapse but a prosecutable crime.

The Bard Recovery IVC Filter — Struts That Broke Loose and Killed 27

When C.R. Bard stopped selling its Recovery inferior vena cava filter in 2005, it did not recall the device or warn the roughly 34,000 patients carrying one inside the largest vein in the body; it replaced the Recovery with a cosmetically modified successor, the G2, and the gap between the promise and the harm was by then already documented in Bard’s own files. The Recovery was marketed as the first retrievable IVC filter cleared in the United States — a spider-shaped nitinol cage meant to catch blood clots traveling toward the heart and lungs and then, unlike permanent filters, to be removed once the danger passed. A confidential study Bard commissioned in 2004 found the opposite of a safe device: the Recovery carried higher relative risk of death, filter fracture, and migration than every competing filter on the market.

The failure mechanism was mechanical and lethal. The Recovery’s thin struts fractured, and the broken fragments — sharp lengths of nitinol — embolized through the bloodstream into the right heart and the pulmonary arteries, or the whole filter migrated and perforated the vena cava wall. A December 2005 internal Bard document, later obtained by NBC News, recorded that the Recovery had an “11.5 times higher reporting rate for filter embolization deaths” than all other vena cava filters combined. Bard had recruited a veteran regulatory specialist, Kay Fuller, to shepherd the FDA clearance; Fuller refused to sign the application over safety concerns, and the application reached the FDA bearing what she says is a forged version of her signature.

Rather than recall the Recovery after the 2004 report urged urgent investigation, Bard withdrew it from sale in 2005 and sold the G2 — a device Bard’s own records show it knew was fracturing and migrating within four months of clearance. The death toll surfaced not through a regulator but through a year-long NBC News investigation broadcast in September 2015, which linked the Recovery to at least 27 deaths and more than 300 non-fatal injuries. Thousands of suits consolidated into a multidistrict litigation in Arizona, and the first bellwether — Sherr-Una Booker, whose G2 fractured and required open-heart surgery — produced a $3.6 million verdict in March 2018, including $2 million in punitive damages. The FDA never recalled the Recovery; the legend of the “retrievable” filter ended as a case study in replacing a known-defective implant instead of retrieving it.